More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR).
Researchers at Celldex Therapeutics, Inc and Nerviano Medical Science Srl report elimination of the most common childhood cancer by an ADC in xenografted mice expressing either wild-type or mutated ALK.
Global antibacterial innovation network CARB-X announced during an AMR business conference in Berlin that Germany has joined the CARB-X partnership.
Under a three-year agreement, British pharma giant AstraZeneca plc pays €20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response to cancer immune therapies.
Copenhagen-based SNIPR BIOME Aps raised €43m in a series A financing led by seed investor Lundbeckfonden Emerge (Copenhagen) and LSP and co-financed by North-East Family Office (Copenhagen) and Wellington Partners (Munich).
Researchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes.
Seventure Partners has announced the first close of its second microbiome fund designed to put €200m in 20 companies developing microbiome-based health solutions.
Swiss immunology and immuno-oncology specialist Numab Innovation AG has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics Inc.
Biogen has strengthened its portfolio with Nightstar Therapeutics, a British gene therapy specialist for rare inherited eye disorders.